EE102 Economic Burden of Metastatic Castration-Resistant Prostate Cancer, By Line of Treatment, in Medicare Beneficiaries, 2014-2019
نویسندگان
چکیده
This retrospective study describes healthcare resource utilization (HRU) and cost of care, by line therapy (LOT), in Medicare Fee-for-Service (FFS) beneficiaries diagnosed with mCRPC initiating systemic treatment. A cohort was conducted using the 100% sample FFS medical, pharmacy, enrollment data. Male were included if: a) initiated between January 1, 2015 September 30, 2019 (index date: treatment start date), b) aged 66+ at index, c) continuously enrolled for 12 months pre-index prior exposure to androgen deprivation ≥3 post index. claims-based algorithm used identify up four LOT. Direct all-cause prostate-cancer (PC) related (based on primary diagnosis) payments patient out pocket (OOP) costs evaluated during each LOT adjusted 2020 USD per month (PPPM). Among 17,760 patients who 1LOT, 41.8% progressed 2LOT; 17.9% 3LOT; 7.4% 4LOT. Mean age index: 77.5 (SD: 7.2) years. (SD) PPPM OOP were: 1LOT: $11,011 ($9,579) $835 ($839), 2LOT: $14,383 ($25,848) $1,024 ($1,715), 3LOT: $14,923 ($19,058) $1,152 ($1,855), 4LOT: $15,863 ($19,276) $1,276 ($2,084). medical increased from 1LOT $5,281 ($10,074) 4LOT $13,285 ($19,197), pharmacy decreased 2LOT $6,310 ($9,801) $2,578 ($4,506). Prostate cancer-related comprised 75.7% 68.8% 2LOT, 58.2% 3LOT, 50.8% male mCRPC, care subsequent LOT, while after second therapy.
منابع مشابه
Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel
متن کامل
Navigating Treatment of Metastatic Castration- Resistant Prostate Cancer: Nursing Perspectives.
BACKGROUND Treatment of metastatic castration-resistant prostate cancer (mCRPC) has evolved rapidly. In particular, five new treatments that extend survival in mCRPC have been approved since 2010, including the chemotherapy cabazitaxel (Jevtana®), hormonal agents abiraterone (Zytiga®) and enzalutamide (Xtandi®), vaccine sipuleucel-T (Provenge®), and radiopharmaceutical radium-223 (Xofigo®); all...
متن کاملEnzalutamide for the treatment of metastatic castration-resistant prostate cancer
In recent years, several nonhormonal and hormonal agents, including enzalutamide, have been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC) on the basis of improved overall survival in prospective clinical trials. The incorporation of these agents has revolutionized the treatment of CRPC but has also raised the question of what is the ideal sequence of admin...
متن کاملTreatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide.
Prostate cancer is initially responsive to androgen deprivation therapy, but most patients eventually develop castration-resistant disease. Enzalutamide is an androgen receptor (AR) inhibitor that targets several steps in the AR signaling pathway and has shown significant efficacy in the treatment of metastatic castration-resistant prostate cancer in patients with or without prior chemotherapy....
متن کاملProstate Cancer Management of Metastatic Castration-resistant Prostate Cancer
The management of men with metastatic castration-resistant prostate cancer (CRPC) has taken several leaps forwards in the last two years, with the demonstration of improved overall survival with three novel agents (sipuleucel-T, cabazitaxel and abiraterone acetate) and a significant delay in skeletal-related events observed with denosumab. The pipeline of systemic therapies in prostate cancer r...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2022
ISSN: ['1098-3015', '1524-4733']
DOI: https://doi.org/10.1016/j.jval.2022.04.355